KaloBios Pharma (KBIO) Tops Q2 EPS by 22c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/6/2026
- S&P 500, Nasdaq touch new peaks as Treasury yields cool, oil slips
- Oil slips as Mideast exports, G7 stockpile ease supply concerns
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- Goldman flags 2 key market risks if a climb in yields persists
- Shell CEO says Middle East oil flows reach 80% of prewar levels
Tweet
Share
E-mailGet Alerts KBIO Hot Sheet
Join SI Premium – FREE
KaloBios Pharma (NASDAQ: KBIO) reported Q2 EPS of ($1.46), $0.22 better than the analyst estimate of ($1.68).
For earnings history and earnings-related data on KaloBios Pharma (KBIO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Truist Securities Highlights Two Machinery Names To Own
- Lamb Weston (LW) Tops Q1 EPS by 15c ; Offers Guidance
- Wall Street upgrades Brazilian equities after election first-round surprise
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
